How many drugs treat Spinal muscular atrophy?

Drug Landscape tracks 3 marketed treatments for Spinal muscular atrophy (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/spinal-muscular-atrophy.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Spinal muscular atrophy — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Spinal muscular atrophy (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Spinal muscular atrophy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	First approval
Evrysdi	RISDIPLAM	Roche	Survival of Motor Neuron 2 Splicing Modifier [EPC]	2020-01-01
Spinraza	NUSINERSEN	Biogen Idec	Survival Motor Neuron-2-directed RNA Interaction [EPC]	2016-01-01
Zolgensma	Zolgensma	Novartis Pharmaceuticals

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Biogen Idec · 1 drug in Spinal muscular atrophy
Novartis Pharmaceuticals · 1 drug in Spinal muscular atrophy
Roche · 1 drug in Spinal muscular atrophy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Spinal muscular atrophy:

Cite this brief

Drug Landscape (2026). Spinal muscular atrophy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/spinal-muscular-atrophy. Accessed 2026-06-10.

Spinal muscular atrophy full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing